Best Quality Olaparib Azd-2281 Powder on Factory Supply
|FOB Price:||US $1-2 / gram|
|Min. Order:||1 gram|
|Min. Order||FOB Price|
|1 gram||US $1-2/ gram|
|Payment Terms:||T/T, Western Union, Money Gram, Bitcoins,Bank tansfer,WhatsApp:+8615622635381|
- Model NO.: 763113-22-0
- Customized: Customized
- Suitable for: Elderly, Adult
- Purity: >99%
- Express: TNT, FedEx, EMS, DHL
- Mqq: 10gram
- Export Markets: Global
- Transport Package: Foil Bag or Tin & Well Disguised Package with Fast
- Origin: Guangzhou
- Powder: Yes
- Certification: GMP, ISO 9001, USP, BP
- State: Solid
- Delivery Time: 4-7 Days
- Payment Terms: T/T, Western Union, Money Gram, Bank Transfer;Bitc
- Price: Negotiation
- Trademark: Quanao
- Specification: ISO9001: 2008
- HS Code: 2942000000
laparib (AZD2281, Ku-0059436)
Olaparib (AZD2281, Ku-0059436) is a selective PARP1 / 2 inhibitor with an IC50 of 5 nM / 1 nM in cell-free assays, 300-fold stronger than that of Tankyrase-1. Phase 3
Chemical Name : 4-(3-(1-(cyclopropanecarbonyl)piperazine-4-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one
Solubility (25°C) : DMSO 86 mg/mL warming (197.94 mM) Water 0.002 mg/mL (0.0 mM) Ethanol <1 mg/mL
Stability :-20ºC Powder , 3 years : -80ºC Soluble in solvents 2years
Usage:Olaparib is a potent poly(ADP-ribose) polymerase (PARP) inhibitor. Olaparib has been shown to induce significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. Recent studies show that Olaparib increases radiosensitivity of a lung tumor xenograft, making it a potential candidate for use in combination with radiotherapy.
Ovarian cancer forms in the ovary, one of a pair of female reproductive glands where ova, or eggs, are formed.
Lynparza is a poly ADP-ribose polymerase (PARP) inhibitor that blocks enzymes involved in repairing damaged DNA. It is intended for women with heavily pretreated ovarian cancer that is associated with defective BRCA genes.
"Today's approval constitutes the first of a new class of drugs for treating ovarian cancer," said Richard Pazdur, MD, director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research. "Lynparza is approved for patients with specific abnormalities in the BRCA gene and is an example of how a greater understanding of the underlying mechanisms of disease can lead to targeted, more personalized treatment.
Olapanil is a novel poly-ADP ribose polymerase (PARP) inhibitor, including PARP1, PARP2, and PARP3. PARP mediates a mechanism of DNA repair and plays an important role in DNA damage repair and cell apoptosis. Therefore, the mechanism of DNA damage repair by targeting to cells is mediated by PARP1 and PARCA2 mutant cancer cells Of the critical loopholes in the role, can be used for breast cancer susceptibility gene (BRCA) mutations, platinum-sensitive drug-resistant patients with recurrent severe ovarian cancer maintenance therapy.
Olaparib is a kind of novel poly ADP-ribose polymerase (PARP) inhibitors, including PARP1, PARP2, and PARP3. PARP mediates a DNA-repair mechanism which plays a important role in DNA damage repair and apoptosis, so olaparib specifically targets on the DNA repair mechanism of the targeting cell DNA repair and take effects by attacking the critical vulnerabilities of cancer cells carrying mutations in BRCA1 and BRCA2. Owing to this mechanism, it can be used for the maintenance therapy of patients of severe recurrent ovarian cancer who has breast cancer susceptibility gene (BRCA) mutation as well as being sensitive to platinum drug.
|Telatinib (BAY 57-9352)|